Connect with us

Hi, what are you looking for?

Jewish Business News

Court

UK High Court Favors Teva in Patent Case against AstraZeneca

Teva-Pharmaceutical-Industries

Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that a positive judgment has been given by the UK High Court in support of Teva’s case against AstraZeneca relating to the validity of EP 1, 085, 877 covering the SMART (Single inhaler Maintenance And Reliever Therapy) indication for AstraZeneca’s fixed dose formoterol/budesonide combination product, Symbicort.

The Court agreed with Teva that AstraZeneca’s patent covering the SMART indication of Symbicort was obvious, and rejected AstraZeneca’s proposed amendments to the patent on the basis that they added matter. The case was brought to facilitate Teva’s European launch of its formoterol/budesonide fixed combination product, DuoResp Spiromax which utilizes Teva’s innovative Spiromaxdevice technology.

“Our DuoResp Spiromax product brings effective treatment to the patient in a device that is intuitive and easy to use, ” said Rob Koremans, MD, President and CEO, Teva Global Specialty Medicines. “Yesterday’s judgment is a big step in enabling us to make a difference to people’s lives in the UK and all across Europe.”

This is the latest decision in Teva’s favor in respect of AstraZeneca’s fixed dose, formoterol/budesonide combination product. The Teva Group has previously successfully revoked patents EP 0, 613, 371 and also, EP 1, 014, 993, covering the use of the fixed dose combination in the treatment of asthma and in COPD respectively, and their national equivalents, before the European Patent Office and the Norwegian court.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement
cialis cialis satış